1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
2.1.1 SECONDARY DATA 24
2.1.1.1 Key date from secondary sources 24
2.1.2 PRIMARY DATA 25
2.1.2.1 Key data from primary sources 26
2.1.2.2 Key industry insights 27
2.2 MARKET SIZE ESTIMATION 27
2.2.1 MARKET DATA VALIDATION AND TRIANGULATION 29
2.3 ASSUMPTIONS FOR THE STUDY 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 36
4.1 LIVE CELL IMAGING: MARKET OVERVIEW 36
4.2 LIVE CELL IMAGING MARKET, BY PRODUCT AND SERVICE, 2018 37
4.3 LIVE CELL IMAGING MARKET, BY APPLICATION, 2018 38
4.4 LIVE CELL IMAGING MARKET: GEOGRAPHIC SNAPSHOT 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 DRIVERS 41
5.2.1.1 Rising adoption of high-content screening techniques in drug discovery 41
5.2.1.2 Rising incidence of cancer 41
5.2.1.3 Growing availability of funds for research 41
5.2.2 RESTRAINTS 42
5.2.2.1 High cost of high-content screening systems 42
5.2.3 OPPORTUNITIES 42
5.2.3.1 Emerging markets 42
5.2.3.2 Application of HCS in personalized medicine 43
5.2.4 CHALLENGES 44
5.2.4.1 Maintaining cell viability & cellular environment in the culture 44
5.2.4.2 Dearth of skilled professionals 44

6 LIVE CELL IMAGING MARKET, BY PRODUCT & SERVICE 45
6.1 INTRODUCTION 46
6.2 INSTRUMENTS 47
6.2.1 INCREASING DEMAND FOR LIVE CELLS FOR ANALYSIS IN THE BIOTECHNOLOGY AND BIOPHARMACEUTICAL INDUSTRIES TO DRIVE THE ADOPTION OF LIVE CELL IMAGING INSTRUMENTS 47
6.2.2 MICROSCOPES 48
6.2.3 STANDALONE SYSTEMS 50
6.2.4 CELL ANALYZERS 51
6.2.5 ACCESSORIES 51
6.3 CONSUMABLES 52
6.3.1 REAGENTS 53
6.3.1.1 Reagents segment to account for the largest share of the live cell imaging consumables market in 2018 53
6.3.2 ASSAY KITS 54
6.3.2.1 Repeat purchase of assay kits - key driver for market growth 54
6.3.3 MEDIA 55
6.3.3.1 Development of new and advanced technologies has resulted in an increased demand for high-quality media in biomedical research and processing 55
6.3.4 OTHER CONSUMABLES 56
6.4 SOFTWARE 57
6.4.1 TECHNOLOGICAL ADVANCEMENTS IN IMAGE ACQUISITION - A KEY DRIVER FOR MARKET GROWTH 57
6.5 SERVICES 58
6.5.1 AVAILABILITY OF A WIDE RANGE OF SERVICES AND GROWING NUMBER OF INITIATIVES BY KEY PLAYERS TO DRIVE THE SERVICES MARKET 58

7 LIVE CELL IMAGING MARKET, BY APPLICATION 60
7.1 INTRODUCTION 61
7.2 CELL BIOLOGY 62
7.2.1 INCREASING PREVALENCE OF CANCER TO DRIVE THE CELL BIOLOGY APPLICATION SEGMENT 62
7.3 STEM CELLS 63
7.3.1 IMPORTANCE OF STEM CELL RESEARCH HAS BOOSTED INVESTMENTS IN THIS AREA 63
?
7.4 DEVELOPMENTAL BIOLOGY 64
7.4.1 GROWING RESEARCH IN DEVELOPMENTAL BIOLOGY A KEY DRIVER OF MARKET GROWTH 64
7.5 DRUG DISCOVERY 65
7.5.1 USE OF HCS CELL-BASED ASSAYS HAS GROWN IN DRUG DEVELOPMENT STUDIES 65

8 LIVE CELL IMAGING MARKET, BY END USER 67
8.1 INTRODUCTION 68
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 69
8.2.1 INCREASING R&D ACTIVITIES AND THE PATENT CLIFF OF VARIOUS BLOCKBUSTER DRUGS TO INCREASE THE DEMAND FOR LIVE CELL IMAGING PRODUCTS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 69
8.3 ACADEMIC & RESEARCH INSTITUTES 70
8.3.1 DEMAND FOR LIVE CELL IMAGING PRODUCTS TO INCREASE IN ACADEMIC AND RESEARCH INSTITUTES OWING TO THE RISING FOCUS OF THESE END USERS ON STRENGTHENING THEIR OWN DRUG DISCOVERY RESEARCH PROGRAMS 70
8.4 CONTRACT RESEARCH ORGANIZATIONS 71
8.4.1 GROWING OUTSOURCING OF R&D ACTIVITIES BY PHARMACEUTICAL COMPANIES TO DRIVE THE DEMAND FOR LIVE CELL IMAGING SYSTEMS IN CONTRACT RESEARCH ORGANIZATIONS 71

9 LIVE CELL IMAGING MARKET, BY REGION 72
9.1 INTRODUCTION 73
9.2 NORTH AMERICA 74
9.2.1 US 78
9.2.1.1 US dominates the North American live cell imaging market primarily due to the strong trend of pharmaceutical & biotechnology research and the high burden of cancer 78
9.2.2 CANADA 80
9.2.2.1 Government initiatives to promote research and the need to combat cancer are the key factors driving the growth of the live cell imaging market in Canada 80
9.3 EUROPE 83
9.3.1 GERMANY 87
9.3.1.1 Presence of a large number of academic research institutes and increasing R&D spending to drive the demand for live cell imaging in Germany 87
9.3.2 UK 89
9.3.2.1 UK has seen a surge in the prevalence of cancer; by 2030, an estimated 4 million people are expected to be diagnosed with the disease 89
9.3.3 FRANCE 91
9.3.3.1 Growth in the French live cell imaging market is attributed to the large pharmaceutical manufacturing industry and the high public expenditure on R&D in France 91
9.3.4 REST OF EUROPE (ROE) 93
9.4 ASIA PACIFIC 96
9.4.1 CHINA 100
9.4.1.1 China to register the highest growth rate in the Asia Pacific live cell imaging market during the forecast period 100
9.4.2 JAPAN 102
9.4.2.1 Increasing aging population, rising prominence for regenerative medicine research, and increasing number of researchers to support market growth in Japan 102
9.4.3 INDIA 104
9.4.3.1 Favorable changes in foreign direct investment (FDI) regulations in the pharmaceutical industry to drive market growth 104
9.4.4 ROAPAC 106
9.5 ROW 108

10 COMPETITIVE LANDSCAPE 113
10.1 INTRODUCTION 113
10.2 LIVE CELL IMAGING MARKET SHARE ANALYSIS (2017) 114
10.3 COMPETITIVE LEADERSHIP MAPPING 116
10.3.1 VISIONARY LEADERS 116
10.3.2 INNOVATORS 116
10.3.3 DYNAMIC DIFFERENTIATORS 116
10.3.4 EMERGING COMPANIES 117
10.4 COMPETITIVE SCENARIO 118

11 COMPANY PROFILES 120
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 DANAHER CORPORATION 120
11.2 CARL ZEISS AG 125
11.3 NIKON CORPORATION 128
11.4 OLYMPUS CORPORATION 131
11.5 PERKINELMER 133
11.6 GE HEALTHCARE 135
11.7 BRUKER 137
11.8 THERMO FISHER SCIENTIFIC 140
11.9 SARTORIUS AG 143
11.10 BIOTEK INSTRUMENTS 145
11.11 ETALUMA 147
11.12 CYTOSMART TECHNOLOGIES 149
11.13 NANOENTEK 150
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
?

12 APPENDIX 151
12.1 DISCUSSION GUIDE: LIVE CELL IMAGING MARKET 151
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 155
12.3 AVAILABLE CUSTOMIZATIONS 157
12.4 RELATED REPORTS 157
12.5 AUTHOR DETAILS 158